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Objectives. This study sought to determine the safety and efficacy
of a single bolus of intravenous dofetilide, a pure class III
antiarrhythmic agent, for the termination of sustained atrial
fibrillation or flutter.
Background. Dofetilide is a highly selective blocker of the rapid
component of the delayed rectifier current causing action poten-
tial prolongation. These effects, and preliminary clinical data,
suggest that it may be effective in the treatment of atrial fibrilla-
tion and flutter.
Methods. Ninety-one patients with sustained atrial fibrillation
(75 patients) or flutter (16 patients) were entered into a double-blind,
randomized multicenter study of one of two doses of dofetilide
(4 or 8 mg/kg body weight) or placebo.
Results. Dofetilide effectively terminated the arrhythmia in 31%
of patients receiving 8 mg/kg, a statistically significant difference
from those receiving 4 mg/kg (conversion rate 12.5%, p < 0.05) or
placebo (no conversion, p < 0.01). Patients with atrial flutter had
a greater response to dofetilide (54% conversion rate) than those
with atrial fibrillation (14.5% conversion rate, p < 0.001).
Conclusions. Intravenous dofetilide can convert sustained
atrial fibrillation or flutter to sinus rhythm. However, its efficacy
is greater in flutter—a response that contrasts with the poorer
response seen with class I agents. This finding potentially repre-
sents an important advance in the pharmacologic termination of
atrial flutter.
(J Am Coll Cardiol 1997;29:385–90)
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Antiarrhythmic therapy for atrial fibrillation or atrial flutter
has two goals: 1) pharmacologic termination of the arrhythmia,
and 2) maintenance of sinus rhythm after pharmacologic or
electrical reversion. Although a number of antiarrhythmic
agents are relatively effective in achieving one or both of these
goals, the overall efficacy rate and prevalence of side effects are
such that the continued development of newer agents is
warranted. Quinidine, a class I antiarrhythmic agent, is still
widely used in the United States. However, it has frequent
noncardiac side effects, and concern about the potential for an
adverse effect of quinidine on mortality (1) in patients treated
for atrial fibrillation has led to a reconsideration of its role in
treating this arrhythmia (1,2). Coupled with specific concerns
about quinidine is a general interest in the development of
alternative agents to the class I antiarrhythmic drugs, and
attention is now focusing on agents that primarily prolong
refractoriness rather than slowing conduction (3–5).
Dofetilide is a highly selective blocker of the inward potas-
sium current and appears to specifically block the rapid
component of the delayed rectifier current (IKr) (6–8). As
such, it results in prolongation of the action potential duration,
with a resultant increase in myocardial refractoriness, and is
classified as a class III agent (9). Preliminary investigations
with dofetilide show it to be effective in the prevention of
ventricular arrhythmias (9–11), and an unblinded, uncon-
trolled study of intravenous dofetilide (12) suggested that it
may be effective in the termination of both atrial fibrillation
and flutter. The electrophysiologic properties of dofetilide,
namely, a prolongation of refractoriness without conduction
slowing, suggest that it might be particularly useful in atrial
flutter. This arrhythmia is relatively refractory to termination
by class I agents, and an alternative to electrical cardioversion
would be an attractive option. The purpose of the present
study was to investigate the efficacy and safety of two different
intravenous doses of dofetilide compared with placebo for the
termination of sustained atrial fibrillation or flutter and to
investigate whether a differential effect of dofetilide was ap-
parent on these arrhythmias.
Methods
Patients. This was a double-blinded study of intravenous
dofetilide or placebo in 91 patients with atrial fibrillation or
flutter recruited from 13 sites (see Appendix). Patients had
sustained arrhythmia for a minimum of 2 weeks and a maxi-
mum of 6 months at the time of study entry. Rest ventricular
response was at least 70 beats/min, and all patients with atrial
fibrillation received a minimum of 2 weeks of therapeutic
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warfarin therapy before study entry. All antiarrhythmic drugs,
as well as diltiazem, verapamil and beta-adrenergic blocking
agents were withdrawn for at least 5 half-lives before study
drug administration, and subjects receiving drugs that may
prolong the QT interval, such as antidepressants or phenothia-
zines, were excluded. Serum potassium concentrations were
required to be within the range 4.0 to 5.5 mEq/liter and serum
magnesium 1.5 to 2.5 mEq/liter. Subjects .75 years old,
women of childbearing potential, patients with pre-excitation
syndromes and those with uncontrolled hypertension were
excluded, as were patients with previous electrocardiographic
(ECG) documentation of high degree atrioventricular block
(unless protected by a permanent pacemaker), those with a
QRS duration $180 ms or a QT interval .500 ms. The study
was approved by the Institutional Review Board of each
participating investigator’s institution, and written informed
consent was obtained from each patient.
Protocol. After a 30-min period of continuous ECG mon-
itoring, patients received an infusion of randomly assigned
therapy consisting of either 4.0 or 8.0 mg/kg body weight of
dofetilide or placebo. The medication was administered as a
15-min infusion, and neither the investigator nor the patient
were aware of the identity of the therapy. At the end of the
infusion, subjects were continuously monitored for an addi-
tional 6 h, during which period no additional antiarrhythmic
agents were administered.
During the baseline 30-min period, the period of infusion
and the subsequent 45 min, heart rate and blood pressure were
measured every 15 min. The ventricular response to atrial
fibrillation was determined from a 1-min rhythm strip recorded
every 15 min. A positive response to therapy was defined as
conversion to normal sinus rhythm. Blood samples for serum
dofetilide levels were obtained immediately before infusion, at
the end of the infusion and at 15-min intervals for the next
45 min. In those patients converting to sinus rhythm, blood was
drawn for analysis of dofetilide levels at the time of conversion.
Plasma samples were frozen and stored at 2208C. Samples
were later analyzed by a double-antibody radioimmunoassay
(Harris Lab).
In the early stage of the study, subjects who did not revert
to sinus rhythm after 1 h could receive an open label infusion
of 8.0 mg/kg of dofetilide, provided that the initial infusion did
not cause side effects and did not prolong the uncorrected QT
interval by .80 ms. The identity of the initial infusion was not
known at the time of the second infusion. This option to
administer open label 8.0 mg/kg was terminated early in the
study because of safety concerns originating from other ongo-
ing studies of dofetilide that suggested that torsade de pointes
might be more prevalent at higher dose levels. Only eight
patients received this second infusion.
Statistical analysis. Comparison of conversion rates be-
tween groups was made by chi-square analysis and the Fisher
exact test. A p value ,0.05 was considered statistically signif-
icant. Ninety-five percent confidence intervals were calculated
according to the standard method of Ghosh (13). Comparison
of ECG variables in the treatment and placebo groups was
made by the Kruskal-Wallis nonparametric analysis of variance
test and Dunn’s multiple comparisons test using commercially
available statistical software (Instat).
Results
Ninety-one patients, recruited from 13 centers, were en-
rolled in the study. The baseline characteristics of patients in
each of the three study arms were determined by history and
clinical examination by the individual investigators and are
reported in Table 1. These characteristics did not differ among
groups. Seventy-five patients had atrial fibrillation, and 16 had
atrial flutter. There was a nonsignificant trend toward a longer
duration of arrhythmia in patients with atrial fibrillation than
in those with atrial flutter (61 days, 95% confidence interval
(CI) 48 to 74 vs. 37 days, CI 18 to 57, p 5 0.08). The incidence
of heart failure did not differ between patients with atrial
flutter and those with atrial fibrillation. Patients were random-
ized to receive placebo (n5 30) or 4 mg/kg (n5 32) or 8 mg/kg
(n 5 29) of dofetilide. Of the eight patients receiving an open
label infusion of dofetilide after the double-blind phase, five
had received an initial infusion of placebo, one had received
4 mg/kg of dofetilide, and two had received 8 mg/kg of
dofetilide.
Conversion to sinus rhythm. In the double-blind phase, 4
of 32 patients (12.5%, CI 5% to 28%) receiving the lower dose
of dofetilide converted to sinus rhythm (including 2 with a
history of heart failure) compared with 9 of 29 (31%, CI 17.3%
to 49.2%) receiving 8 mg/kg (including 4 with a history of heart
failure). No patient converted after receiving placebo. The
response to 8 mg/kg was significantly greater than that to either
placebo (p , 0.001) or 4 mg/kg of dofetilide (p , 0.05) but the
conversion rate for patients receiving 4 mg/kg did not differ
significantly from that for placebo. Three of the eight patients
receiving the open label dose of dofetilide converted to sinus
rhythm. The initial double-blind therapy in these three patients
consisted of placebo in one subject, 4 mg/kg of dofetilide in one
and 8 mg/kg in the third. Conversion to sinus rhythm after open
label dofetilide was not included in the efficacy analysis of
dofetilide.
Of 16 patients with atrial flutter on the prestudy electrocar-
diogram, 5 were randomized to receive placebo, 3 to 4 mg/kg
and 8 to 8 mg/kg of dofetilide. No patient with atrial flutter
received the open label dose of dofetilide. No patient with
flutter receiving placebo reverted to sinus rhythm compared
with one of three receiving the lower dofetilide dose and five of
eight receiving the higher dose. Conversion to sinus rhythm
Abbreviations and Acronyms
ANOVA 5 analysis of variance
CI 5 confidence interval
ECG 5 electrocardiogram, electrocardiographic
IKr 5 delayed inward rectifier current
QTc 5 corrected QT interval
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from flutter was sudden, without change in the ventricular
response or evidence of slowing of the atrial rate. The overall
response rate of 54% (6 of 11 patients) for subjects with atrial
flutter receiving either dose of dofetilide was higher than the
overall rate of 14.3% (7 of 49) of subjects with atrial fibrillation
who received either dose of dofetilide (p , 0.01).
Effects on heart rate, blood pressure and ECG. As shown
in Table 2, heart rate remained unchanged at the end of the
infusion (15-min values). Dofetilide had no effect on blood
pressure or QRS duration. The QTc intervals in the placebo
group remained unchanged from baseline to after infusion,
whereas a statistically significant increase in this interval
occurred in dofetilide-treated patients. The maximal QTc
interval did not differ between patients receiving 4 or 8 mg/kg.
The mean dofetilide plasma levels for patients receiving
both doses of dofetilide are reported in Table 3. Peak levels
were consistently higher in the higher dose group. Plasma
levels were available at the time of conversion in six patients
and ranged from 1.40 to 18.4 ng/ml. This wide range reflected
the range of time at which conversion occurred after com-
mencement of the infusion. Plasma levels in patients with
conversion to sinus rhythm corrected for time of conversion,
did not differ from those without conversion.
Markers of efficacy. In view of the minimal efficacy of
4 mg/kg of dofetilide to produce restoration of sinus rhythm,
markers of efficacy were sought only in the higher dosage
group. Other than the presence of atrial flutter, no clear-cut
markers were identified that might predict which patients may
Table 1. Baseline Clinical Characteristics
Dofetilide
Placebo
(n 5 30)
4 mg/kg
(n 5 32)
8 mg/kg
(n 5 29)
Mean age (yr) 63.6 65.7 66.5
Men 22 23 22
Women 10 6 8
Sustained AF 29 21 25
Sustained AFL 3 8 5
Duration of AF/AFL (mo)
Median 1.4 1.4 1.7
Mean 2.2 1.8 2.6
Range 0.5–6.8 0.5–5.5 0.5–7.9
Mean left atrial size (cm) 4.4* 4.6† 4.5‡
Range 3–7 3–6 4–6
NYHA functional class
I 11 11 16
II 18 13 9
III 3 4 5
IV 0 1 0
Cardiovascular disease§
Arterial hypertension 14 16 14
Congestive heart failure 18 12 7
Idopathic dilated cardiomyopathy 8 5 4
Hypertrophic cardiomyopathy 0 1 2
Exertional angina 6 4 7
Myocardial infarction 4 5 6
Valvular heart disease 1 2 3
None 5 6 8
*n5 30. †n5 28. ‡n5 29. §More than one condition can coexist in a patient. Data presented are number of patients,
unless otherwise indicated. AF 5 atrial fibrillation; AFL 5 atrial flutter; NYHA 5 New York Heart Association.
Table 2. Effect of Intravenous Dofetilide on Heart Rate and Corrected QT Interval*
HR (beats/min) QTc (ms)
Baseline End of Infusion Baseline End of Infusion
Placebo infusion (n 5 29) 87.9 6 21 87.5 6 20 434.5 6 39 427.2 6 38
Dofetilide
4 mg/kg (n 5 31) 89.0 6 19 90.8 6 17 437.9 6 53 492.2 6 60†
8 mg/kg (n 5 28) 90.6 6 18 90.1 6 21 421.8 6 43 491.1 6 76†
*All patients were in atrial fibrillation or flutter at time of measurement. †p , 0.01 versus placebo at end of infusion;
no significant difference between corrected QT intervals (QTc) at the two dofetilide doses was seen. Data presented are
mean value 6 SD. HR 5 heart rate.
387JACC Vol. 29, No. 2 FALK ET AL.
February 1997:385–90 IV DOFETILIDE FOR AF AND FLUTTER
respond to dofetilide. Specifically, there was no significant
difference in the median arrhythmia duration in patients with
(29.5 days, CI 9.9 to 73) than those without conversion (40
days, CI 32 to 71). Median QTc intervals in patients with
conversion measured 30 min after drug infusion also did not
differ from those without conversion (495 ms, 95% CI 442 to
582 vs. 478 ms, 454 to 516 ms), and no clinical indicator could
be identified that appeared to favor conversion.
Adverse effects. Adverse effects of the dofetilide infusion
were limited to the cardiovascular system. Torsade de pointes
occurred in 2 (3.2%) of 62 patients who received at least one
dose of dofetilide (during the double-blind infusion of 4 mg/kg
in one; during open label infusion of 8 mg/kg after an initial
placebo infusion in the other). Detailed rhythm strips were
unavailable for review in the former patient, but the latter had
a permanent pacemaker in the VVI mode that was pacing at 80
beats/min. The baseline QTc interval was 515 ms, primarily
due to the widened, paced QRS complex. During the infusion
of dofetilide, the QTc interval prolonged to .600 ms (precise
measurement could not be made because of R on T ectopic
beats), followed by multiple episodes of torsade de pointes.
Two other patients, both of whom had received an initial
infusion of placebo, developed marked QT prolongation asso-
ciated with increasing premature ventricular contractions dur-
ing open label infusion (8 mg/kg) of dofetilide. The infusion
was terminated in one patient because the QTc interval
increased from 400 ms at baseline to 620 ms during dofetilide
infusion. Neither of these patients developed sustained or
symptomatic arrhythmia. Three additional patients developed
short runs of wide QRS complex tachycardia during the
infusion of 8 mg/kg without hemodynamic consequences. In
one of these patients, monomorphic wide QRS complex beats
occurring during the 8-mg/kg infusion were, on review of the
tracings, due to aberrantly conducted supraventricular beats.
Inadequate documentation in the other two subjects precluded
detailed analysis of the arrhythmia.
Discussion
This study indicates that intravenous dofetilide, a class III
antiarrhythmic agent, may restore sinus rhythm in patients with
atrial flutter or fibrillation of at least 2 weeks in duration.
Conversion was more likely to occur in patients receiving 8
than 4 mg/kg, and atrial flutter was a more responsive arrhyth-
mia than atrial fibrillation.
Previous studies. The relatively low conversion rate of
12.5% after 4 mg/kg and the higher rate of 31% after 8 mg/kg
of dofetilide are in contrast to data of Suttorp et al. (12). These
investigators studied 24 patients with atrial fibrillation or
flutter treated with 2.5, 4 or 8 mg/kg of dofetilide, administered
intravenously over 15 min and repeated 15 min after the end of
infusion if conversion had not occurred. The overall efficacy
rate was 53% for 19 patients with atrial fibrillation and 80% for
5 with atrial flutter.
The study by Suttorp et al. (12) was not performed in
blinded manner and although no difference in response rate
was seen among dosage groups, the numbers are too small for
statistical analysis. The mean duration of atrial arrhythmia in
the Suttorp et al. study was 32 6 43 days (range 1 to 150), and
seven patients had an arrhythmia duration of ,1 day. This
finding is in contrast to those of the present study (mean
duration of arrhythmia 62 days, range 14 to 240, median 42).
The success of pharmacologic conversion of atrial fibrillation is
related to the duration of the arrhythmia. In patients with
atrial fibrillation of #1 week in duration, ;40% of those
treated with placebo will convert to sinus rhythm within 24 h
(14,15), and in subjects with recent-onset atrial fibrillation
(#48 h), the efficacy of short term drug therapy may be even
higher (15). In contrast, arrhythmia duration $1 week rarely
converts spontaneously, and drug efficacy decreases to the
range seen in the present study (16). Thus, it is possible that in
the Suttorp et al. study (12), either the inclusion of patients
with a short arrhythmia duration or with less severe heart
disease may have increased the likelihood of conversion. Our
conversion rates are closer to those of a recently published
small study (17) in which two of six patients with atrial
fibrillation receiving 8 mg/kg of dofetilide and two of nine
patients given 12 mg/kg of dofetilide had conversion to sinus
rhythm, an overall response rate of only 27% (17).
Atrial flutter. A striking finding in the current study is the
relatively high conversion rate in the group of patients with
atrial flutter. Previous studies of type I antiarrhythmic agents
(16,18,19) have suggested that pharmacologic conversion of
atrial flutter is unusual and occurs less frequently than in
patients with atrial fibrillation. In an early survey of the
reported efficacy of procainamide, Kayden et al. (20) reported
a conversion rate of only 13% in patients with atrial flutter
compared with 88% of those with atrial fibrillation of #2
weeks in duration. Olshansky et al. (21) failed to produce
pharmacologic conversion to sinus rhythm in any of seven
patients treated with intravenous procainamide despite a pro-
longation of atrial cycle length in all seven. Class IC agents are
also documented to have a poor efficacy in terminating atrial
flutter (19). In contrast, our observations are consistent with
those of the study by Suttorp et al. (12), in which 4 of 5 patients
with atrial flutter reverted to sinus rhythm after dofetilide
infusion, and with a recently published study (19) comparing
dofetilide with flecainide, in which only 1 of 11 patients with
atrial flutter reverted to sinus rhythm after 2 mg/kg of intra-
venous flecainide compared with 7 of 10 subjects receiving 4 to
8 mg/kg of dofetilide.
Table 3. Mean Plasma Dofetilide Concentrations
Time From Start of
Infusion (min)
Mean 6 SD Dofetilide Concentration
(ng/ml)
4 mg/kg 8 mg/kg
15* 4.35 6 2.2 10.7 6 5.2
30 2.4 6 1.6 3.7 6 1.6
45 1.8 6 1.0 3.4 6 1.6
60 1.7 6 0.8 3.1 6 1.3
*Levels at 15 min represent end of infusion.
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The conversion of atrial flutter with dofetilide is compatible
with its class III properties. Atrial flutter is most commonly due
to a macroreentrant arrhythmia around the right atrium (22).
Drugs that primarily slow atrial conduction, such as flecainide,
might not be expected to terminate atrial flutter, although the
cycle length may be prolonged (3,19,23). Type IA agents, which
both prolong refractoriness and slow conduction, may affect
the atrium such that, although cycle length is slowed, an
excitable gap persists allowing persistent arrhythmia (19). In
contrast, selective prolongation of refractoriness would favor
termination of the arrhythmia by decreasing the excitable gap.
This effect of class III agents has been proved in experimental
models (23), and the observation that atrial flutter cycle length
lengthens minimally before conversion after dofetilide sup-
ports this as a mechanism in humans (19).
Adverse effects. A concern of therapy with class III agents
is the potential for provocation of torsade de pointes. Action
potential prolongation is associated with the development of
early afterdepolarizations in animal models (24,25), and early
afterdepolarizations are believed to be responsible for many
cases of human torsade de pointes. As previously described
(22,26), and as confirmed in the present study, dofetilide
produces a significant prolongation of the QT interval. Tor-
sade de pointes occurred in two patients in our study, neither
of whom required specific treatment for the arrhythmia other
than termination of the dofetilide infusion. Other cases of
torsade have occurred with both oral and intravenous dofetil-
ide (17), but preliminary data show that a dose based on
creatinine clearance as well as weight may reduce the potential
for excessive drug levels, at least in patients receiving oral
therapy (Pfizer, data on file). Whether dofetilide has a greater
or lesser propensity for the provocation of torsade de pointes
than other class III agents, such as sotalol (27,28), remains to
be determined.
Short runs of wide QRS complex tachycardia were seen in
three patients during dofetilide infusion while the patients
were still in atrial fibrillation. Dofetilide manifests electro-
physiologic features that may predispose to aberrant ventricu-
lar conduction, and aberrant conduction during atrial fibrilla-
tion may be difficult to distinguish from short runs of
ventricular tachycardia. Crijns et al. (29) performed an elec-
trophysiologic study in a patient receiving dofetilide who
manifested periods of wide QRS complex tachycardia. Dofeti-
lide caused an increased propensity to aberrant conduction.
However, the same investigators (30) also reported isolated
bundle branch reentry in a patient with coexistent dofetilide-
induced aberrantly conducted supraventricular beats during
atrial fibrillation, thus raising the possibility that the drug may
predispose to sustained bundle branch reentry in susceptible
patients. At least one of three patients with nonsustained wide
QRS complex arrhythmias in our study had aberrantly con-
ducted atrial fibrillation confirmed by the presence of identical
complexes after atrial premature beats once sinus rhythm had
been restored. As noted, inadequate data in the other two
patients precluded a diagnosis of the origin of their wide QRS
complex beats.
In contrast to the proarrhythmia provoked by dofetilide, no
patient developed evidence of hemodynamic deterioration
despite a history of heart failure in 30 of the 61 patients
receiving active drug. Although only a single dose of the drug
was given, the lack of a negative hemodynamic effect is
compatible with findings in previous animal studies (31) and
probably relates to the pure class III actions of dofetilide.
Conclusions. Intravenous dofetilide was effective in termi-
nating some cases of atrial fibrillation of moderate duration
but was significantly more effective in terminating atrial flutter.
The effect of dofetilide on atrial flutter, which is generally
considered a relatively pharmacologically resistant arrhythmia,
is consistent with the pure class III effect of dofetilide and
confirms observations in small unblind, nonrandomized studies
of intravenous dofetilide (12,19,22). Although the higher dose
of dofetilide (8 mg/kg) was more effective in arrhythmia
termination, the propensity to cause torsade de pointes in
some patients limits further investigation into the antifibrilla-
tory effects of higher doses.
Intravenous dofetilide has potential as a short-term antiar-
rhythmic agent in patients with atrial flutter, but in this study it
was considerably less effective in patients with atrial fibrilla-
tion. The efficacy of a drug for terminating an arrhythmia is not
necessarily equivalent to its efficacy for preventing recurrence,
and ongoing studies are evaluating the safety and efficacy or
oral dofetilide for prevention of recurrent atrial fibrillation and
flutter.
Appendix
The Intravenous Dofetilide Investigators
Rodney H. Falk, MD, Boston City Hospital, Boston, Massachusetts (20
patients randomized); Steven Singh, MD, Veterans Affairs Medical Center,
Washington, D.C. (17 patients randomized, 4 patients screen failure); Bramah N.
Singh, MD, PhD, Veterans Affairs Wadsworth Hospital Medical Center, Los
Angeles, California (10 patients randomized, 1 patient screen failure); Bruce
Shively, MD, Veterans Affairs Hospital, Albequerque, New Mexico (9 patients
randomized); James Maloney, MD, Cleveland Clinic, Cleveland, Ohio (6 patients
randomized); Koonlawee Nademanee, MD, Denver General Hospital, Denver,
Colorado (6 patients randomized, 2 patients screen failure); Raymond Yee, MD,
University Hospital, London, Ontario, Canada (6 patients randomized); Gregory
K. Feld, University of California San Diego Medical Center, San Diego, California
(6 patients randomized); Dan Roden, MD, Vanderbilt University, Nashville,
Tennessee (5 patients randomized, 1 patient screen failure); John Onufer, MD,
Cardiovascular Associates, Ltd., Hague Medical Center, Norfolk, Virginia (4
patients randomized); John C. Somberg, MD, University of Health Sciences, The
Chicago Medical School, North Chicago, Illinois (3 patients randomized); Elliot
M. Antman, MD, Brigham and Women’s Hospital, Boston, Massachusetts (2
patients randomized); Lameh Fananapazir, MD, National Institutes of Health,
Bethesda, Maryland (2 patients randomized).
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